科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score - here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7(TD)) - measures severity from 0 to 42. Insufficient evidence exists on whether disease activity states, defined by categorical UAS7(TD) scores, correlate with other patient-reported outcomes and treatment response. Objectives To evaluate and compare categorical UAS7(TD) scores with selected measures of disease-related quality of life and impact. Methods Data from three randomized clinical trials of omalizumab in CSU were pooled. Continuous UAS7(TD) scores were categorized into five disease activity states: urticaria-free, well-controlled, mild, moderate and severe urticaria. Total scores from the Dermatology Life Quality Index; the Chronic Urticaria Quality of Life questionnaire; and questions on sleep and daily activity interference, presence of angioedema and diphenhydramine use were compared within categorized UAS7(TD) disease-state scores, using ANOVA for analysis at different time points and mixed-effects regressions for analysis of all data pooled. Results Pooled analyses showed that categorical UAS7(TD) disease states accurately predicted differences among treated patients with CSU with different levels of disease activity. A consistent pattern existed between categories, with higher-activity disease states associated with significantly higher impact and an increase in angioedema frequency. Results at different treatment time points were consistent. Conclusions Categorical UAS7(TD) disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy.
- 出版日期2017-10
